Background: Prostate cancer has a propensity to invade and grow along nerves, a
INTRODUCTION
An important determinant of tumor behavior is the ability to breach basement membranes and spread outside the confines of the organ of origin. The classic paradigm of tumor metastasis is that of tumor spread via blood vessels and lymphatic channels. However, prostate cancer has long been recognized to show a propensity to invade and grow along prostatic nerves, which lead out of the prostate to the pelvic plexus (1) . While this phenomenon, known as perineural invasion (PNI), has classically been thought to occur because nerves provide cancer cells a low resistance path out of the prostate, recent studies suggest a more dynamic interaction (2) (3) (4) . Prostate cancer cells adjacent to nerves show increased proliferation compared to those located further away (5, 6) . Capsular nerve count as assessed by image analysis has also been shown to be significantly higher in areas adjacent to prostate tumor than normal tissue, suggesting the induction of nerve growth (7) . Thus, the perineural space may be a microenvironment that promotes both cancer spread and growth.
Despite the biologic plausibility of PNI being a potential determinant of prostate cancer behavior, an association between PNI and prostate cancer progression continues to be a subject of debate, and PNI is not routinely reported on prostate cancer pathology reports. While some studies have failed to find an association between PNI and prostate cancer outcomes (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) , many others have demonstrated the clinical significance of PNI detection in both biopsy (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) and prostatectomy (38-43) samples. In Tables 1 and 2 we summarize previously published studies assessing the association between PNI in prostate biopsy ( Table 1 ) and radical prostatectomy ( Table 2 ) specimens and risk of recurrence and cancer-specific mortality. Author Manuscript Published OnlineFirst on January 6, 2017; DOI: 10.1158/1055-9965.EPI- Most prior studies looking at PNI as a prognostic factor in radical prostatectomy specimens have focused on biochemical recurrence as the outcome of interest. Only three studies (18, 26, 38) have examined PNI as a predictor of prostate cancer-specific mortality in men treated with surgery, with only one of them (38) showing PNI to predict mortality on multivariate analysis. This is critical as most men who develop a biochemical recurrence are not destined to develop lethal prostate cancer (44) (45) (46) . Our work focuses on exploring the relationship between PNI and prostate cancer-specific deaths in a novel fashion: no prior study has explored this association among initially untreated men. Using two large population-based prostate cancer cohorts, we set out to determine whether PNI is an independent predictor of lethal prostate cancer in men treated with watchful waiting or radical prostatectomy, as well as to evaluate the association between PNI and tumor markers of disease aggressiveness.
MATERIALS AND METHODS

Study Population
The study was nested within two prostate cancer cohorts: the Swedish Watchful Waiting Cohort and the U.S. Health Professionals Follow-Up Study (HPFS) prostate tumor cohort. The Swedish cohort included men from the southeast region of Sweden diagnosed with clinically localized prostate cancer between 1977 and 1999 after undergoing transurethral resection of the prostate (TURP) for benign prostatic hyperplasia (BPH) (47, 48) . As per the standard of care in Sweden at the time, these men were followed expectantly as part of a watchful waiting protocol. Men who went on to develop symptomatic locally advanced or metastatic disease were treated with androgen deprivation therapy. We retrieved archival TURP tissue specimens for 661 of the men who form the study cohort, as described in more detail elsewhere (49) , with 615 of these specimens ultimately being evaluated for PNI.
In 1986, the HPFS enrolled 51,529 male health professionals aged 40 to 75 years, all of who were cancer-free at baseline. The men are followed every two years with detailed questionnaires to collect information on lifestyle factors, medications, and health-related information. For this project, we included men diagnosed with incident prostate cancer between 1986 and 2004 for whom archival prostatectomy (95%) or TURP (5%) tissue specimens were available. Our sample of 849 cases represents 49% of the prostate cancer cases in the cohort that were treated with radical prostatectomy. Details of the HPFS prostate tumor cohort are described elsewhere (50, 51) . Importantly, men whose tumors were evaluated for PNI did not differ from those men who were not sampled in terms of their clinical characteristics. Tumor proliferation, apoptosis and angiogenesis were also examined in a subset of the patients in the HPFS. Ki67 immunostaining (N=399 cases) was performed on tumor tissue microarrays using a polyclonal antibody (Vector Labs), diluted 1:2,000 after citrate-based antigen retrieval, and scored by quantitative image analysis. A TUNEL assay (N=335) on tissue microarrays was used to assess apoptosis. For a subset of patients (N=339), whole section specimens were analyzed for morphologic markers of tumor angiogenesis (vessel density, area, diameter, and irregularity) by staining for the CD34 marker and using image analysis as described previously (52) .
Statistical Analysis
Associations between PNI status and clinical and pathologic characteristics were assessed using the chi-square test for categorical variables and generalized linear models or the Wilcoxon rank sum test for continuous variables. Ki67 and TUNEL scores were categorized into quartiles to account for their non-normal distributions, while angiogenesis parameters were log-transformed.
Multivariable regression analyses were performed to determine whether PNI is an independent predictor of lethal prostate cancer. In the Swedish cohort, a nested casecontrol design was devised to maximize efficiency in the pathologic review and included men who died of prostate cancer at any point during follow-up as cases (N=228), and men who survived for 10 years or more as controls (N=387). Unconditional logistic regression was used to calculate odds ratios (OR) and 95% confidence intervals (CI).
The HPFS was analyzed using Cox proportional hazards regression to calculate hazard ratios (HR) and 95% CI. The event was defined as the development of bone or visceral metastases or death due to prostate cancer. Person-time was calculated from the date of diagnosis to development of metastases, death due to prostate cancer (whichever occurred earlier), death from other causes, or the end of follow-up (December 2011).
Competing risks regression was used to assess the impact of death from other causes on the effect estimates. 
Swedish Watchful Waiting Cohort
PNI was present in 43 of 615 (7%) prostate cancer cases in the Swedish cohort.
Patients with tumors harboring PNI tended to be slightly older (mean age 74.8 years vs. Table 3 ). PNI was strongly associated with high Gleason grade; two-thirds of tumors with PNI were Gleason grade ≥8 tumors compared to only 16% of tumors without PNI (p trend <0.001). PNI was also positively associated with tumor volume and presence of hgPIN, a precursor lesion of prostate cancer (p=0.01). There was no association between the presence of PNI and chronic inflammation or any of the atrophy lesions.
years,
PNI was strongly associated with risk of lethal prostate cancer (see Table 4 ). Men with evidence of PNI in tumor tissue were seven times more likely to die of cancer than men without PNI (crude OR 7.4, 95% CI 3.6, 16.6; p<0.001). After adjustment for clinical factors, there remained a non-statistically significant higher risk of prostate cancer-related death in men with PNI (OR 1.9, 95% CI 0.8, 5.1; p=0.17). This association was similar for men with high and low Gleason grade tumors as well as large and small volume tumors (data not shown).
Health Professionals Follow-Up Study
In the HPFS, which predominantly includes radical prostatectomy specimens (95%), PNI was present in 370 of 849 cases (44%), a higher proportion than in the Swedish cohort ( Table 3) . Men with tumors exhibiting PNI did not differ from those without PNI in age at diagnosis (mean 66.1 vs. 65.9 years, p=0.68) nor preoperative PSA levels (median 6.6 vs. 6.1 ng/dL, p=0.12). Similar to the Swedish cohort, there was a strong association between the presence of PNI and higher Gleason grade (p trend <0.001).
Moreover, PNI was significantly more common with higher pathologic TNM stage 
had a low number of events such that our analysis was likely underpowered to detect significant effect modification by Gleason grade and stage.
There was no association between presence of PNI and extent of tumor proliferation or apoptosis ( Table 5) . Tumors harboring PNI did, however, demonstrate increased tumor angiogenesis, as manifested by higher microvessel density (p=0.008) and smaller vessel diameter and area (p<0.001). The differences in angiogenesis parameters were consistent across Gleason grade (analyses not shown). 
DISCUSSION
In two independent prostate cancer cohorts, we found PNI to be rarely present in low Gleason grade tumors but much more common in high Gleason grade disease.
Moreover, in both a watchful waiting and prostatectomy cohort, PNI conferred a twofold higher risk of lethal prostate cancer even after adjustment for other pathologic factors.
The association between PNI and lethal prostate cancer was apparent even among men with high grade cancers, and may indicate an independent mechanism by which cancers cells can leave the prostate.
The prevalence of PNI among RP specimens in our study (44%) is lower than the prevalence reported by most prior studies, which was typically in the range of 50-80% (see Table 2 ). This is likely explained by the fact that we used a strict definition of PNI, that of circumferential encirclement of nerves by malignant glands. In contrast, prior studies reporting a higher PNI prevalence either did not describe how PNI was defined (14, 19, 20, 25, 39) or used vague descriptions such as presence of tumor cells "in the perineural space" (16, 18) or "along the perineural sheath" (21) . Because the perineural space can often be difficult to identify using H&E stains alone, abutment of the perineural space by both malignant and benign glands can, in the absence of circumferential involvement, be misinterpreted as PNI (53, 54) lower prevalence of PNI in our study may alternately be explained by the fact that we did not have access to all H&E slides for some of the HPFS cases.
Although the associations between PNI and lethal prostate cancer were similar, there was a profound difference in the prevalence of PNI by cohort (7% in the Swedish cohort and 44% in the HPFS). This difference can likely explained by differences in the zonal location of the tumors. The HPFS prostatectomy cases were primarily peripheral zone tumors whereas tumors from the Swedish cases arose primarily in the transition zone.
Indeed, among 40 HPFS TURP specimens, the PNI prevalence of 12% was on par with the Swedish TURP cohort. Although this suggests that there may be unique differences in the prostate microenvironment within these two zones, it is also possible that transition zone tumors may be smaller and therefore less likely to be diagnosed by a limited transurethral resection.
The novelty of our study is that it is one of the few studies, and the largest to date, to assess the association between PNI in radical prostatectomy (as opposed to biopsy) specimens and prostate cancer-specific mortality (as opposed to biochemical recurrence). Of the more than 30 studies that have examined the association between PNI in radical prostatectomy specimens and prostate cancer outcomes (see Table 2 ), only three (18, 26, 38) have assessed whether PNI predicts distant metastases or death, with the remainder focusing on biochemical recurrence as the outcome of interest. This is important given that most men who develop a biochemical recurrence are not destined to die of their disease (44) (45) (46) . Two of these studies (18, 26) did not find PNI to be an independent predictor of cancer-specific mortality, although both were significantly smaller (361 and 273 patients) and had shorter follow-up (median 3. (18, 26) . The third study, of 535 Norwegian men who were followed for a median of 7.4 years after radical prostatectomy, showed the presence of PNI in the prostatectomy specimen to be associated with a worse cancer-specific survival even after adjustment for preoperative PSA, prostatectomy Gleason score, pathologic stage, and surgical margin status (38). In contrast, multiple prior studies have shown PNI discovered on needle core biopsy to predict adverse clinical outcomes, including mortality (see Table 1 ). A recent study of 451 men treated with radical prostatectomy at the Mayo Clinic and followed for a median of 13 years thereafter found PNI in the biopsy specimen to predict cancer-specific mortality independent of Gleason grade (29). The prognostic value of PNI in biopsy specimens may be related to its correlation with extraprostatic extension in prostatectomy specimens (56) .
years) than our study
PNI, defined as the presence of cancer cells within any of the three connective tissue layers enveloping a nerve, was first described in the mid-1800's in head and neck cancers (3). PNI was initially thought to be a variant of lymphatic spread, until it was shown that the perineural space is devoid of lymphatics (57) . Among 78 prostatectomy specimens with extraprostatic extension, Villers et al showed spread to occur exclusively along the prostatic nerves in half (2) . This and similar studies were the basis for the prevalent belief that the interface between prostatic nerves and prostate tissue is a low-resistance plane that provides a convenient route for cancer spread out of the prostate.
In contrast, recent research increasingly suggests that PNI is a manifestation of a complex interaction between nerve and cancer cells Two candidate mechanisms have been identified to account for the pro-survival effect of PNI. NFΚB and its targets PIM-2 and DAD-1, which together constitute part of an antiapoptotic pathway, have been shown to be overexpressed in prostate cancer cells associated with nerves compared to those located further away (6). The upstream activator of NFΚB, NCAM, is upregulated in the setting of nerve injury (60) . Caveolin-1, a scaffolding protein with anti-apoptotic properties that is expressed by perineural stromal cells during wound repair, has likewise been found to be overexpressed in PNI (61) . It is therefore possible that prostate cancer invasion of nerves and subsequent nerve injury results in upregulation of these anti-apoptotic pathways. We did identify a potential novel biological mechanism by which PNI could influence prostate cancer aggressiveness. Our finding of an association between the presence of PNI and increased angiogenesis has not been previously reported in prostate cancer, nor in any other tumors with a propensity for perineural spread, and presents a promising avenue for future study. 
The strength of our study lies in its large sample size, prospective data collection, additional tissue biomarker data, and complete follow-up. Unlike most previous studies, all specimens in both cohorts were reviewed systematically for the presence or absence of PNI by a single dedicated genitourinary pathologist. This likely increased the validity of information for our analysis as PNI is not considered a required component of the histopathologic evaluation of prostate cancer specimens by the College of American Pathologists, and is therefore likely underreported in clinical practice (62, 63) . The difference in prevalence of PNI in the TURP tumors, which arise primarily in the transitional zone, and prostatectomy samples, which are primarily peripheral zone cancers, provides further evidence of these cancers representing distinct biological entities. Despite the large sample size and standardized pathologic review, the low prevalence of PNI in the Swedish cohort likely significantly decreased the precision of our effect estimates, and possibly accounts for why PNI did not reach statistical significance as an independent predictor in this cohort. Importantly, men in the HPFS cohort who underwent RP had predominantly low to intermediate-grade, organ-confined tumors. Given the increasing use of active surveillance for low-risk tumors and the expected reverse stage migration precipitated by declining rates of PSA screening, it is expected that an increasing number of patients undergoing RP in the contemporary era will have high-risk disease. Given the power limitations of our subgroup analyses, it is unclear whether our findings are therefore generalizable to a more contemporary population of men undergoing RP.
In summary, we present evidence that PNI is a strong predictor of lethal prostate cancer among men undergoing radical prostatectomy and describe for the first time an 
